The first large shipments of a new anti-malaria drug using a semisynthetic artemisinin derivative have been delivered to countries in Africa through a partnership between French drugmaker Sanofi and global health organization PATH. The semisynthetic artemisinin has been shown to be an exact replica of the botanically derived version, giving the new drug the same level of effectiveness.

Full Story:
BioSpectrum Asia

Related Summaries